You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

TENOFOVIR DISOPROXIL FUMARATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Tenofovir Disoproxil Fumarate patents expire, and when can generic versions of Tenofovir Disoproxil Fumarate launch?

Tenofovir Disoproxil Fumarate is a drug marketed by Aurobindo Pharma, Chartwell, Chartwell Rx, Cipla, Hetero Labs Ltd Iii, Macleods Pharms Ltd, Norvium Bioscience, Qilu, Reyoung, Strides Pharma, and Teva Pharms Usa. and is included in twelve NDAs.

The generic ingredient in TENOFOVIR DISOPROXIL FUMARATE is tenofovir disoproxil fumarate. There are forty-two drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the tenofovir disoproxil fumarate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tenofovir Disoproxil Fumarate

A generic version of TENOFOVIR DISOPROXIL FUMARATE was approved as tenofovir disoproxil fumarate by TEVA PHARMS USA on March 18th, 2015.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for TENOFOVIR DISOPROXIL FUMARATE?
  • What are the global sales for TENOFOVIR DISOPROXIL FUMARATE?
  • What is Average Wholesale Price for TENOFOVIR DISOPROXIL FUMARATE?
Drug patent expirations by year for TENOFOVIR DISOPROXIL FUMARATE
Drug Prices for TENOFOVIR DISOPROXIL FUMARATE

See drug prices for TENOFOVIR DISOPROXIL FUMARATE

Recent Clinical Trials for TENOFOVIR DISOPROXIL FUMARATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Assistance Publique - Hôpitaux de ParisPhase 3
Wits Health Consortium (Pty) LtdPhase 3
London School of Hygiene and Tropical MedicinePhase 3

See all TENOFOVIR DISOPROXIL FUMARATE clinical trials

Paragraph IV (Patent) Challenges for TENOFOVIR DISOPROXIL FUMARATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VIREAD Tablets tenofovir disoproxil fumarate 150 mg, 200 mg, and 250 mg 021356 1 2012-05-17
VIREAD Tablets tenofovir disoproxil fumarate 300 mg 021356 1 2010-01-26

US Patents and Regulatory Information for TENOFOVIR DISOPROXIL FUMARATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aurobindo Pharma TENOFOVIR DISOPROXIL FUMARATE tenofovir disoproxil fumarate TABLET;ORAL 090647-001 Jan 26, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Reyoung TENOFOVIR DISOPROXIL FUMARATE tenofovir disoproxil fumarate TABLET;ORAL 211337-001 Mar 2, 2023 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cipla TENOFOVIR DISOPROXIL FUMARATE tenofovir disoproxil fumarate TABLET;ORAL 078800-001 Jan 26, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.